A Cambridge company with £1.7 million of annual Revenue and a £17.6 million pre-tax loss is not an obvious candidate for renewed attention. Yet 4basebio PLC (LSE:4BB) has spent 2026 assembling the pieces of a commercial-stage business: a new management team, a new Manufacturing site, a new product line and, on 26 August 2026, a Marketing agreement with a gene therapy contract manufacturer that puts its synthetic DNA in front of a wider set of clinical programmes.

The question is whether that activity converts into orders quickly enough. 4basebio ended 2025 with £17.8 million of cash and has since drawn a further €7 million under an existing Debt facility, which the board says funds the group into late 2027. At 475p on 2 September 2026, capitalising the company at roughly £73.6 million, the market is pricing a platform, not a profit stream.

Genezen agreement puts hpDNA into viral vector Supply chains

The most significant recent development came on 26 August 2026, when 4basebio announced a non-exclusive Strategic Collaboration and Marketing Agreement with Genezen, a viral vector contract development and manufacturing organisation backed by US Private Equity firm Ampersand Capital Partners.

Under the agreement, Genezen gains access to 4basebio's hpDNA synthetic DNA across research-use-only, high-quality and GMP grades, to be used as starting material in Drug Development and clinical programmes, and the two companies will work together on sales and technical presentations. Financial terms were not disclosed, and the arrangement is not exclusive.

The commercial logic is that viral vector manufacturing traditionally relies on plasmid DNA grown in bacteria, which carries antibiotic resistance genes and contamination risk; 4basebio's enzymatic, cell-free process removes both. Christine Wolosin, 4basebio's Chief Commercial Officer, framed the deal as a Partnership with a manufacturer that shares the company's focus on safety. For a Business whose bottleneck is customer access rather than technology, a CDMO channel matters more than the undisclosed terms suggest.

What 4basebio actually does

4basebio is a biotechnology company headquartered in Cambridge that manufactures synthetic DNA and related nucleic acids for the advanced therapy sector. Its opDNA and hpDNA products are made enzymatically and cell-free, rather than grown in bacterial fermentation, and are sold as starting material for gene and cell therapies, genome editing, mRNA production and DNA vaccines.

Revenue comes from research-grade DNA sales, GMP-grade material supplied into clinical programmes, and development work with pharmaceutical partners. The customer base exceeded 125 partners at the end of 2025 and the Patent estate had grown to 33 families. An MHRA GMP licence for the UK DNA facility, granted in April 2025, is the regulatory step that allows its material to be used in human trials.

The product range widened on 11 May 2026, when 4basebio launched an enzymatic single-stranded DNA platform producing constructs of up to 10,000 nucleotides with protected ends, aimed at CRISPR gene editing and homology directed repair. Capacity is expanding too: on 31 March 2026 the company leased roughly 26,500 sq ft at Bar Hill, Cambridge from Peterhouse, including 7,500 sq ft of laboratory space, with occupation expected in late summer 2026.

FY2025 results: revenue up 81%, losses wider

Results for the year ended 31 December 2025, published on 20 May 2026, showed revenue of £1.7 million, up 81% from £0.9 million in 2024, with clinical-stage projects contributing £1.1 million and DNA sales doubling. Gross Profit was £974,000, a 57.5% margin.

Below that line the numbers reflect a company still building. Operating loss and loss before tax were both £17.6 million, with a net loss of £16.9 million against £12.3 million in 2024, and basic and diluted loss per share of £1.09 versus £0.94. Cash and cash equivalents fell to £17.8 million at 31 December 2025 from £34.6 million a year earlier, while non-current financial liabilities rose to £15.6 million from £14.3 million. The €7 million drawdown under the Deutsche Balaton Facility in April 2026 was disclosed as funding the group into late 2027.

Chief executive Dr Amy Walker described 2025 as "a step-change for the Company" and said the group expects "significant growth in revenues 2026 and beyond"; Executive Chair Dr Manja Boerman called the company "at a pivotal point in its development". Half-year results published on 29 September 2025 showed H1 2025 revenue of £1.2 million, a pre-tax loss of £8.2 million and cash of £26.1 million, implying a lighter second half for sales.

Catalysts to watch

The nearest is the half-year report for the six months to 30 June 2026; last year's was published at the end of September. It will be the first hard read on whether the 81% growth rate carried into 2026 and on the rate of cash consumption.

Beyond that, three things could move the story: conversion of the Genezen relationship into named supply contracts; delivery of the clinical supply agreement signed on 20 May 2026 with an unnamed cancer immunotherapy developer, which the company said should generate approximately a seven-figure revenue stream over 12 months from GMP opDNA supplied into a Phase II trial; and commissioning of the Bar Hill site, which lifts the capacity constraint on larger GMP orders. Adoption of the ssDNA platform is slower-burning but potentially larger.

Risks investors should watch

Cash is the central issue. An annual operating loss of £17.6 million against year-end cash of £17.8 million leaves the company dependent on the Deutsche Balaton facility, and funding stated only into late 2027 implies another financing decision well before then, with dilution or further debt both plausible.

Concentration is a second risk: £1.1 million of FY2025's £1.7 million revenue came from clinical-stage projects, so the delay of a single programme is material. Management noted at the 2025 half-year that certain mRNA Vaccine programmes had been deferred beyond 2025 because of US policy changes, a reminder that end-market Demand is not in the company's control. The Genezen agreement is non-exclusive and carries no guaranteed volume.

There is also execution risk around near-complete Leadership turnover: a new chief executive in February 2026, a chief commercial officer and chief operating officer in March, and a chief financial officer announced in May. With 15.48 million shares in issue and a 52-week range of 425p to 885p, the stock is thinly capitalised and volatile.

Outlook

4basebio has moved from proving its chemistry to proving its commercial model, and 2026 has been about laying groundwork rather than banking revenue. The measurable tests are close at hand: interim results, the Bar Hill move, and whether partnerships such as the Genezen agreement translate into disclosed contracts. Until revenue scales materially against a cost base running near £18 million a year, the funding runway remains the dominant variable, and progress is best judged on order flow and cash consumption rather than announcements.